These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 28392137)

  • 1. Brain-derived neurotrophic factor levels under chronic natalizumab treatment in multiple sclerosis. A preliminary report.
    Văcăraş V; Major ZZ; Buzoianu AD
    Neurol Neurochir Pol; 2017; 51(3):221-226. PubMed ID: 28392137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis.
    Signoriello E; Lanzillo R; Brescia Morra V; Di Iorio G; Fratta M; Carotenuto A; Lus G
    Mult Scler; 2016 Jun; 22(7):921-5. PubMed ID: 26453682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis.
    Amor S; van der Star BJ; Bosca I; Raffel J; Gnanapavan S; Watchorn J; Kuhle J; Giovannoni G; Baker D; Malaspina A; Puentes F
    Mult Scler; 2014 Sep; 20(10):1355-62. PubMed ID: 24515731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The balance of pro-inflammatory and trophic factors in multiple sclerosis patients: effects of acute relapse and immunomodulatory treatment.
    Lindquist S; Hassinger S; Lindquist JA; Sailer M
    Mult Scler; 2011 Jul; 17(7):851-66. PubMed ID: 21561957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of glatiramer acetate on peripheral blood brain-derived neurotrophic factor and phosphorylated TrkB levels in relapsing-remitting multiple sclerosis.
    Vacaras V; Major ZZ; Muresanu DF; Krausz TL; Marginean I; Buzoianu DA
    CNS Neurol Disord Drug Targets; 2014; 13(4):647-51. PubMed ID: 24938775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-132-3p, miR-106b-5p, and miR-19b-3p Are Associated with Brain-Derived Neurotrophic Factor Production and Clinical Activity in Multiple Sclerosis: A Pilot Study.
    Sağır F; Ersoy Tunalı N; Tombul T; Koral G; Çırak S; Yılmaz V; Türkoğlu R; Tüzün E
    Genet Test Mol Biomarkers; 2021 Nov; 25(11):720-726. PubMed ID: 34788141
    [No Abstract]   [Full Text] [Related]  

  • 7. Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy.
    Vennegoor A; Rispens T; Van Oosten BW; Wattjes MP; Wondergem MJ; Teunissen CE; Van der Kleij D; Uitdehaag BM; Polman CH; Killestein J
    Mult Scler; 2015 Apr; 21(4):481-4. PubMed ID: 25078275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy.
    Caggiula M; Batocchi AP; Frisullo G; Angelucci F; Patanella AK; Sancricca C; Nociti V; Tonali PA; Mirabella M
    Clin Immunol; 2006 Jan; 118(1):77-82. PubMed ID: 16275091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients.
    Basnyat P; Hagman S; Kolasa M; Koivisto K; Verkkoniemi-Ahola A; Airas L; Elovaara I
    Mult Scler Relat Disord; 2015 Jul; 4(4):334-8. PubMed ID: 26195052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
    Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
    Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomized Trial Evaluating Various Administration Routes of Natalizumab in Multiple Sclerosis.
    Plavina T; Fox EJ; Lucas N; Muralidharan KK; Mikol D
    J Clin Pharmacol; 2016 Oct; 56(10):1254-62. PubMed ID: 26835603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased serum levels of soluble CD14 indicate stable multiple sclerosis.
    Lutterotti A; Kuenz B; Gredler V; Khalil M; Ehling R; Gneiss C; Egg R; Deisenhammer F; Berger T; Reindl M
    J Neuroimmunol; 2006 Dec; 181(1-2):145-9. PubMed ID: 17046070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three cases of herpes zoster radiculitis in MS patients treated with natalizumab.
    Yamout BI; Abou Zeid N; Taha AJ; Zeineddine MM; Khoury SJ
    Mult Scler Relat Disord; 2016 Sep; 9():122-4. PubMed ID: 27645358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natalizumab Modifies Catecholamines Levels Present in Patients with Relapsing- Remitting Multiple Sclerosis.
    Escribano BM; Aguilar-Luque M; Bahamonde C; Conde C; Lillo R; Sanchez-Lopez F; Giraldo AI; Cruz AH; Luque E; Gascon F; Aguera E; Tunez I
    Curr Pharm Des; 2016; 22(31):4876-4880. PubMed ID: 27396595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A longitudinal observation of brain-derived neurotrophic factor mRNA levels in patients with relapsing-remitting multiple sclerosis.
    Liguori M; Fera F; Patitucci A; Manna I; Condino F; Valentino P; Telarico P; Cerasa A; Gioia MC; di Palma G; Quattrone A
    Brain Res; 2009 Feb; 1256():123-8. PubMed ID: 19071096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is natalizumab a breakthrough in the treatment of multiple sclerosis?
    Doggrell SA
    Expert Opin Pharmacother; 2003 Jun; 4(6):999-1001. PubMed ID: 12783595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.
    Holmén C; Piehl F; Hillert J; Fogdell-Hahn A; Lundkvist M; Karlberg E; Nilsson P; Dahle C; Feltelius N; Svenningsson A; Lycke J; Olsson T
    Mult Scler; 2011 Jun; 17(6):708-19. PubMed ID: 21228027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythroblastaemia in natalizumab-treated patients with multiple sclerosis.
    La Gioia S; Seghezzi M; Barcella V; Dominoni P; Mecca T; Frigeni B; Conti MZ; Vedovello M; Vidali M; Rottoli M; Buoro S
    Mult Scler Relat Disord; 2016 Jul; 8():141-4. PubMed ID: 27456890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone.
    Öhrfelt A; Axelsson M; Malmeström C; Novakova L; Heslegrave A; Blennow K; Lycke J; Zetterberg H
    Mult Scler; 2016 Oct; 22(12):1587-1595. PubMed ID: 26754805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate.
    Azoulay D; Vachapova V; Shihman B; Miler A; Karni A
    J Neuroimmunol; 2005 Oct; 167(1-2):215-8. PubMed ID: 16083971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.